• Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal

    Author: Reutersarticle author: ReutersID: 1659976485163897300Mon, 2022-08-08 16:02 LONDON: Pfizer Inc. on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment. Pfizer will pay $68.50 per GBT share, which represents a 7.3 percent premium to its Friday closing price. The deal is at a more than 40 percent premium where GBT was trading before the Wall Street...

  • Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal

    Pfizer Inc is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics , the latest in a series of acquisitions to combat a potential slowdown in COVID-19 products demand as cases fall.

  • Pfizer Buying Global Blood Therapeutics In $5.4B Deal

    NEW YORK (AP) – Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 […]

    • WTMJ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic

    • KESQ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 million last year. Pfizer

  • Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic

    • KESQ

    Pfizer buying Global Blood Therapeutics in $5.4B deal

    Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic. GBT is the developer of Oxbryta tablets, which directly targets the root cause of sickle cell disease. Oxbryta sales were about $195 million last year. Pfizer

  • Pfizer Buys Global Blood Therapeutics In $5.4 Billion Deal

    Pfizer Inc. agreed on Monday to pay $5.4 billion in cash for Global Blood Therapeutics, a maker of sickle cell drugs, as it seeks to cash in on increased revenue from its COVID-19 vaccine and treatment. Pfizer will pay $68.50 per GBT share, representing a 7.3% premium to Friday’s closing price. The deal carries a […]

  • Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

    Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. The post Pfizer to buy Global Blood Therapeutics in $5.4 billion deal first appeared on WRAL TechWire.

  • Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal

    By Mrinalika Roy and Michael Erman (Reuters) - Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood

    • cbssf

    Pfizer to buy South SF-based Global Blood Therapeutics in $5.4B deal

    Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

  • Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal

    Published by Reuters UK (Reuters) -Pfizer Inc is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown --->READ MORE